Celldex Therapeutics (CLDX) : 5 brokerage houses believe that Celldex Therapeutics (CLDX) is a Strong Buy at current levels. 4 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Celldex Therapeutics (CLDX). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 9 Wall Street Analysts endorse the stock as a Buy with a rating of 1.89.
Celldex Therapeutics (CLDX) : The most positive equity analysts on Celldex Therapeutics (CLDX) expects the shares to touch $24, whereas, the least positive believes that the stock will trade at $3 in the short term. The company is covered by 8 Wall Street Brokerage Firms. The average price target for shares are $8.75 with an expected fluctuation of $6.8 from the mean.
Celldex Therapeutics, Inc. has lost 14.48% in the last five trading days and dropped 19.92% in the last 4 weeks. Celldex Therapeutics, Inc. has dropped 10.21% during the last 3-month period . Year-to-Date the stock performance stands at -75.89%. Celldex Therapeutics (NASDAQ:CLDX): On Tuesdays trading session , Opening price of the stock was $3.92 with an intraday high of $4.01. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $3.78. However, the stock managed to close at $3.78, a loss of 3.08% for the day. On the previous day, the stock had closed at $3.9. The total traded volume of the day was 2,892,592 shares.
Celldex Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases. Its lead drug candidates include rindopepimut also referred to as Rintega and CDX-110 and glembatumumab vedotin also referred to as CDX-011. Its early-stage drug candidates in clinical development, includes varlilumab also referred to as CDX-1127, a fully human therapeutic monoclonal antibody for cancer indications, CDX-1401, a targeted immunotherapeutic for cancer indications and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor. CDX-014 is a preclinical product under development for the treatment of cancer.